A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Serelaxin (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms RELAX-AHF-ASIA
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 Jul 2017 Status changed from recruiting to discontinued.
- 06 Jun 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
- 06 Jun 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.